Related Experiment Video
Updated: Apr 24, 2026

Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
Polyphosphoester-based nanoparticles with viscous flow core enhanced therapeutic efficacy by improved intracellular
Yin-Chu Ma1, Jun-Xia Wang, Wei Tao
1School of Medical Engineering, Hefei University of Technology , Hefei, Anhui 230009, People's Republic of China.
Abstract:
The intracellular drug release rate from the hydrophobic core of self-assembled nanoparticles can significantly affect the therapeutic efficacy. Currently, the hydrophobic core of many polymeric nanoparticles which are usually composed of poly(ε-caprolactone) (PCL), polylactide (PLA), or poly(D, L-lactide-co-glycolide) (PLGA) may hinder the diffusion of drug from the core because of their glassy state at room temperature. To investigate the effect of the hydrophobic core state on therapeutic efficacy, we synthesized an amphiphilic diblock copolymers of hydrophilic poly(ethylene glycol) (PEG) and hydrophobic polyphosphoester, which were in a viscous flow state at room temperature. The obtained copolymers self-assembled into core-shell nanoparticles, which efficiently encapsulate doxorubicin (DOX) in the hydrophobic polyphosphoester core (NP(PPE)/DOX). As speculated, compared with the nanoparticles bearing glassy core (hydrophobic PLA core, NP(PLA)/DOX), the encapsulated DOX was more rapidly released from NP(PPE)/DOX with viscous flow core, resulting in significantly increased cytotoxicity. Accordingly, the improved intracellular drug release from viscous flow core enhances the inhibition of tumor growth, suggesting the nanoparticles bearing viscous flow core show great potential in cancer therapy.
More Related Videos
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Bioavailability Enhancement: Drug Permeability Enhancement
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Drug Release Characteristics

